Malásia - inglês - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ep plus group sdn. bhd. - macrogol 4,000 -

Bélgica - inglês - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - sodium sulfate decahydrate 12,9 g/1000 ml - eq. sodium sulfate anhydrous 5,68 g/1000 ml; potassium chloride 0,75 g/1000 ml; macrogol 59 g/1000 ml; sodium chloride 1,46 g/1000 ml; sodium hydrogen carbonate 1,68 g/1000 ml - oral solution - macrogol 4000 59 mg/ml; potassium chloride 0.75 mg/ml; sodium sulfate 12.9 mg/ml; sodium bicarbonate 1.68 mg/ml; sodium chloride 1.46 mg/ml - macrogol, combinations

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

dendy pharmaceuticals pty ltd - macrogol 3350, quantity: 1 g/g - solution, powder for - excipient ingredients: - decrease/reduce/relieve constipation ; aperient/laxative ; helps reduce occurrence of constipation

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - macrogol 3350, quantity: 13125 mg; potassium chloride, quantity: 46.6 mg; sodium chloride, quantity: 350.7 mg; sodium bicarbonate, quantity: 178.5 mg - powder, oral - excipient ingredients: acesulfame potassium - for effective relief from constipation, treatment of constipation, and treatment of faecal impaction defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by the physical examination of the abdomen and rectum, in adults and children 12 years and over.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - macrogol 3350, quantity: 6562.5 mg; sodium bicarbonate, quantity: 89.25 mg; potassium chloride, quantity: 23.3 mg; sodium chloride, quantity: 175.35 mg - powder, oral - excipient ingredients: acesulfame potassium - for effective relief from constipation and treatment of chronic constipation in adults and children aged 2 years and older. for resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum, or the rectum and colon, confirmed by physical examination of abdomen and rectum, in adults and children 2 years and older. for prevention of recurrence of faecal impaction in children aged 2 years and older. use in children 2 years and older should be limited to 12 weeks except under medical supervision.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

key pharmaceuticals pty ltd - macrogol 3350, quantity: 1 g/g - powder - excipient ingredients: - for effective relief from constipation and treatment of chronic constipation. softens stools.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - macrogol 3350 13.125 g;  ;  ; potassium chloride 0.0466 g; sodium bicarbonate 0.1785 g; sodium chloride 0.3507 g - powder for oral solution - 13.8 g - active: macrogol 3350 13.125 g     potassium chloride 0.0466 g sodium bicarbonate 0.1785 g sodium chloride 0.3507 g excipient: colloidal silicon dioxide lemon lime flavour- me 170 orange flavour 301768 saccharin sodium - for the relief from constipation, treatment of chronic constipation. for resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by physical examination of abdomen and rectum.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - macrogol 3350 6.5625 g;  ;  ; potassium chloride 0.0233 g; sodium bicarbonate 0.0893 g; sodium chloride 0.1754 g - powder for oral solution - 6.9 g - active: macrogol 3350 6.5625 g     potassium chloride 0.0233 g sodium bicarbonate 0.0893 g sodium chloride 0.1754 g excipient: colloidal silicon dioxide lemon lime flavour- me 170 orange flavour 301768 saccharin sodium - for the relief from constipation, treatment of chronic constipation. for resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by physical examination of abdomen and rectum.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 400 mg (equivalent: protease, qty 1600 ph eur unit; equivalent: lipase, qty 40000 ph eur unit; equivalent: amylase, qty 25000 ph eur unit) - capsule, enteric - excipient ingredients: hypromellose phthalate; iron oxide red; titanium dioxide; sodium lauryl sulfate; macrogol 4000; triethyl citrate; iron oxide black; iron oxide yellow; dimeticone 1000; gelatin; cetyl alcohol - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 420 mg (equivalent: lipase, qty 35000 ph eur unit; equivalent: amylase, qty 25200 ph eur unit; equivalent: protease, qty 1400 ph eur unit) - capsule - excipient ingredients: macrogol 4000; hypromellose phthalate; cetyl alcohol; triethyl citrate; dimeticone 1000; gelatin; iron oxide red; iron oxide yellow; iron oxide black; titanium dioxide; sodium lauryl sulfate - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: ? cystic fibrosis ? chronic pancreatitis ? pancreatic surgery ? gastrointestinal bypass surgery (e.g. bilroth ii gastroenterostomy) ? ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)